Cipla
- Advice
- Hold
Cipla Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Cipla
Start SIPCipla Investment Rating
-
Master Rating:
-
Cipla has an operating revenue of Rs. 22,274.15 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 16% is great, ROE of 12% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 38 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 88 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 3,541 | 3,746 | 3,070 | 2,882 |
| Operating Expenses Qtr Cr | 2,961 | 3,090 | 2,300 | 2,559 |
| Operating Profit Qtr Cr | 938 | 1,061 | 857 | 388 |
| Depreciation Qtr Cr | 130 | 176 | 107 | 117 |
| Interest Qtr Cr | 7 | 8 | 2 | 6 |
| Tax Qtr Cr | 250 | 265 | 221 | 105 |
| Net Profit Qtr Cr | 679 | 720 | 759 | 653 |
Cipla Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 7
- Bearish Moving Average
- ___
- 9
- 20 Day
- 894.6
- 50 Day
- 945.66
- 100 Day
- 992.08
- 200 Day
- 1008.64
- 20 Day
- 878.72
- 50 Day
- 959.26
- 100 Day
- 1029.52
- 200 Day
- 1031.98
Cipla Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 894.42 |
| Second Resistance | 901.14 |
| Third Resistance | 905.67 |
| RSI | 46.71 |
| MFI | 58.82 |
| MACD Single Line | -28.16 |
| MACD | -19.6 |
| Support | |
|---|---|
| First Resistance | 883.17 |
| Second Resistance | 878.64 |
| Third Resistance | 871.92 |
Cipla Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,397,005 | 153,983,601 | 64.24 |
| Week | 2,416,916 | 165,486,256 | 68.47 |
| 1 Month | 2,412,602 | 148,471,546 | 61.54 |
| 6 Month | 1,738,559 | 94,403,736 | 54.3 |
Cipla Result Highlights
Cipla Synopsis
NSE-Medical-Generic Drugs
Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13091.79 Cr. and Equity Capital is Rs. 161.36 Cr. for the Year ended 31/03/2022. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.| Market Cap | 72,684 |
| Sales | 14,154 |
| Shares in Float | 54.08 |
| No of funds | 960 |
| Yield | 0.56 |
| Book Value | 3.23 |
| U/D Vol ratio | 0.7 |
| LTDebt / Equity | |
| Alpha | -0.03 |
| Beta | 0.54 |
Cipla
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 33.61% | 33.61% | 33.61% | |
| Mutual Funds | 14.09% | 13.78% | 13.39% | |
| Insurance Companies | 4.85% | 5.84% | 3.69% | |
| Foreign Portfolio Investors | 28.39% | 27.69% | 27.64% | |
| Financial Institutions/ Banks | 0.11% | 0.09% | 0.04% | |
| Individual Investors | 14.72% | 14.82% | 15.41% | |
| Others | 4.23% | 4.17% | 6.22% |
Cipla Management
| Name | Designation |
|---|---|
| Dr. Y K Hamied | Chairman |
| Mr. M K Hamied | Vice Chairman |
| Ms. Samina Hamied | Executive Vice Chairman |
| Mr. Umang Vohra | Managing Director & Global CEO |
| Mr. S Radhakrishnan | Non Exe.Non Ind.Director |
| Mr. Ashok Sinha | Independent Director |
| Mr. P R Ramesh | Independent Director |
| Mr. Robert Stewart | Independent Director |
| Dr. Peter Mugyenyi | Independent Director |
| Mr. Adil Zainulbhai | Independent Director |
| Ms. Punita Lal | Independent Director |
| Dr. Mandar Vaidya | Independent Director |
Cipla Forecast
Price Estimates
About Company
Cipla FAQs
What is Share Price of Cipla ?
Cipla share price is ₹900 As on 01 April, 2023 | 05:47
What is the Market Cap of Cipla ?
The Market Cap of Cipla is ₹72683.9 Cr As on 01 April, 2023 | 05:47
What is the P/E ratio of Cipla ?
The P/E ratio of Cipla is 27.5 As on 01 April, 2023 | 05:47
What is the PB ratio of Cipla ?
The PB ratio of Cipla is 3.4 As on 01 April, 2023 | 05:47
Is it the right time to invest in Cipla?
Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.
Is Cipla an Indian company?
Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.
Who is the CEO of Cipla?
Umang Vohra has been the CEO of Cipla since 1 September 2016.
What is Cipla's stock price CAGR?
Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.
How to buy Cipla Ltd. shares?
You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.
What is the ROE of Cipla Ltd.?
The Return on Equity of the stock is 13.5% as of March 2022.